Download Files:
Products Details
Product Description
– LtaS-IN-2 (compound 13) is a inhibitor of LTA synthesis, and shows antibacterial activity against S. aureus and S. epidermidis, with the MIC90 of 0.5 μg/mL and 1 μg/mL, respectively. LtaS-IN-2 is a derivative of LtaS-IN-1 (HY-135813)[1].
Web ID
– HY-156416
Shipping
– Room temperature
Applications
– COVID-19-immunoregulation
Molecular Formula
– C24H16F5N3O5S
References
– [1]Douglas EJA, Marshall B, Alghamadi A, et al. Improved Antibacterial Activity of 1,3,4-Oxadiazole-Based Compounds That Restrict Staphylococcus aureus Growth Independent of LtaS Function [published online ahead of print, 2023 Oct 13]. ACS Infect Dis. 2023;10.1021/acsinfecdis.3c00250.
Molecular Weight
– 553.46
SMILES
– O=C(CC1=COC2=CC=C3C=CC=CC3=C21)OCC(NC4=NN=C(O4)C5=CC=C(C=C5)S(F)(F)(F)(F)F)=O
Clinical Information
– No Development Reported
Research Area
– Infection
Solubility
– 10 mM in DMSO
Target
– Bacterial
Pathway
– Anti-infection
Product type
– Reference compound
Disclaimer: All products are for Research use only unless clearly stated otherwise on the product datasheet. Datasheets provided on the website are drafts for reference purpose only and you are requested to always refer to the hard copy included in the kit for your experimentation. Agdia Products are available for delivery only in Canada.
